...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing. World Health Organization - Organisation Mondiale de la Sante, Fondation Merieux, Annecy, France, 7-9 January 2002 - Abstracts
【24h】

Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing. World Health Organization - Organisation Mondiale de la Sante, Fondation Merieux, Annecy, France, 7-9 January 2002 - Abstracts

机译：关于正在或即将进行临床测试的新型佐剂的第三次会议。世界卫生组织-组织Mondiale de la Sante，Merieux基金会，法国阿讷西，2002年1月7日至9日-摘要

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adjuvants exeit critical and unique influences on the quality of immune responses induced by different types (e.g. whole, subunit, synthetic or DNA) of vaccine. Currently, 'alum' is one of the few adjuvants licensed for use in human vaccines. Many recombinant and synthetic peptide vaccine candidate antigens have been shown to be poorly immunogenic when formulated with alum. This has led to the identification and development of a number of new clinically acceptable adjuvants that are more potent and efficacious than the alum-type adjuvants. WHO and the Foundation Merieux jointly organized a meeting (the third in a series) on 'Novel Adjuvants in or Close to Clinical Testing' at the Fondation Merieux, Annecy, France from 7 to 9 January 2002. The present report outlines progress in the development of new adjuvants for clinical use, as presented by participants in the meeting. The main focus of presentations was on development of prophylactic vaccines, using newly developed human-compatible adjuvants for infectious disease, although some results on therapeutic vaccines, particularly for cancer, were also presented. Summaries of previous meetings have been published .
机译：佐剂对疫苗的不同类型（例如完整，亚基，合成或DNA）诱导的免疫反应的质量产生关键而独特的影响。当前，“ alum”是被许可用于人类疫苗的少数佐剂之一。与明矾配制时，许多重组和合成肽疫苗候选抗原已显示出免疫原性差。这导致鉴定和开发了许多新的临床上可接受的佐剂，这些佐剂比明矾型佐剂更有效和有效。世卫组织和Merieux基金会于2002年1月7日至9日在法国阿讷西Merieux基金会联合组织了一次会议（系列中的第三次），涉及“新型佐剂在临床试验中或即将进行临床试验”。本报告概述了该研究的进展会议参与者介绍了一些用于临床的新佐剂。演讲的主要重点是使用新开发的人类相容性佐剂开发传染性疾病的预防性疫苗，尽管也提出了有关治疗性疫苗（尤其是癌症）的一些结果。先前会议的摘要已出版。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号